Join us on Tuesday, August 3^rd for this CME/MOC-accredited webinar
5:00 PM – 6:30 PM ET

Not an official event of the 2021 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO^®, CancerLinQ^®, or Conquer Cancer^® the ASCO Foundation.

This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Lilly, Merck and Taiho Oncology Inc.

Gastric, Gastroesophageal Junction (GEJ) and Esophageal Cancer

• Current approach to the management of newly diagnosed metastatic gastric, GEJ or esophageal cancer
• Design, eligibility criteria and primary findings from the Phase III KEYNOTE-590 study leading to the recent FDA approval of pembrolizumab combined with chemotherapy for patients with advanced esophageal or GEJ carcinoma who are not candidates for surgical resection or definitive chemoradiation; role in clinical practice
• Available efficacy and safety results from the Phase III CheckMate 649 trial supporting the recent FDA approval of nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for locally advanced or metastatic gastric cancer, GEJ cancer and esophageal adenocarcinoma
• Similarities and differences in design, entry criteria and key efficacy and safety outcomes between the Phase III CheckMate 649 and ATTRACTION-4 trials of first-line nivolumab/chemotherapy for advanced gastric and GEJ adenocarcinoma; clinical role of PD-L1 expression levels and implications for clinical practice
• Available efficacy and safety outcomes from the Phase III CheckMate 577 study leading to the recent FDA approval of nivolumab for patients with completely resected esophageal or GEJ cancer with residual disease who have received neoadjuvant chemoradiotherapy; incorporation into current treatment algorithms
• Clinical and biologic factors in the choice of therapy for patients with advanced esophageal cancer; impact of histology on the selection and sequencing of therapy
• Current role of anti-PD-1 monotherapy for patients with relapsed or refractory esophageal cancer
• Frequency of HER2 amplification and mutations in patients with HER2-positive gastric or GEJ cancer; historical management of HER2-positive disease
• Key efficacy and safety findings supporting the recent FDA approval of pembrolizumab in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma (KEYNOTE-811); integration into clinical management
• Available data from the Phase II DESTINY-Gastric01 trial of trastuzumab deruxtecan (T-DXd) for patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen; recent FDA approval and optimal integration into clinical practice
• Spectrum, incidence and severity of toxicities, including interstitial lung disease, with T-DXd in the DESTINY-Gastric01 trial
• Design, eligibility criteria and key endpoints of the ongoing Phase III DESTINY-Gastric04 trial comparing T-DXd to ramucirumab/paclitaxel for patients with HER2-positive metastatic and/or unresectable gastric or GEJ adenocarcinoma who have experienced disease progression on or after a trastuzumab-containing regimen
• Other ongoing evaluations of T-DXd for patients with HER2-amplified or HER2 mutation-positive advanced gastric/GEJ cancer (eg, DESTINY-Gastric03, DPT01)
• Available data with and current role of anti-PD-1/PD-L1 antibodies for patients with locally advanced or metastatic gastric or GEJ cancer; PD-L1 combined positive score and the use and sequencing of immune checkpoint inhibitors
• Biologic rationale for and ongoing investigation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy, targeted therapy and/or other immunotherapies for gastric, GEJ and esophageal cancer (eg, the KEYNOTE-859, KEYNOTE-585, RiME and INTEGRATEIIb trials)
• Optimal integration of ramucirumab into clinical algorithms; other ongoing studies of ramucirumab-containing combination regimens (eg, RAMIRIS, RAMSES/FLOT7)
• Available clinical research supporting the FDA approval of TAS-102 for heavily pretreated metastatic gastric or GEJ cancer; patient selection for TAS-102 in routine practice
• Frequency of fibroblast growth factor receptor 2b (FGFR2b) overexpression in patients with gastric/GEJ cancer; mechanism of action of bemarituzumab
• Emerging data from the Phase II FIGHT trial evaluating bemarituzumab with chemotherapy versus chemotherapy alone as first-line therapy for patients with FGFR2b-positive metastatic gastric/GEJ cancer; FDA breakthrough therapy designation of bemarituzumab for FGFR2b-overexpressing, HER2-negative advanced gastric cancer
• Biologic rationale for targeting CLDN 18.2 in gastric/GEJ cancer; mechanism of action of zolbetuximab
• Available efficacy and safety findings from Phase I/II trials of zolbetuximab; ongoing Phase III trials evaluating zolbetuximab in combination with chemotherapy for patients with CLDN 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma (eg, SPOTLIGHT, GLOW)
• Other promising novel agents and strategies under investigation for gastric, GEJ and esophageal cancer (eg, CAMILLA)

Colorectal Cancer (CRC)

• Clinical and biologic factors in the selection and sequencing of therapy for patients with CRC
• Key efficacy and safety results from the Phase III KEYNOTE-177 study evaluating first-line pembrolizumab versus chemotherapy for patients with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) unresectable or metastatic CRC; FDA approval of pembrolizumab as first-line therapy and implications for clinical practice
• Correlation between primary tumor location and outcomes with EGFR antibody-based regimens; optimal incorporation of cetuximab and panitumumab into treatment algorithms for metastatic CRC
• Current clinical role of anti-PD-1 monotherapy (eg, nivolumab, pembrolizumab) and nivolumab/ipilimumab in the care of patients with MSI-H/dMMR relapsed or refractory metastatic CRC
• Ongoing investigations of immune checkpoint inhibitors alone or in combination with other systemic approaches (eg, chemotherapy, targeted therapy) for MSI-H/dMMR early-stage and advanced CRC (eg, the CheckMate 8HW trial)
• Optimal selection of first-line therapy for patients with BRAF wild-type, microsatellite stable (MSS) metastatic CRC
• Biologic rationale for, available data with and ongoing Phase III investigations of the combination of an anti-angiogenic agent with an immune checkpoint inhibitor (eg, the LEAP-017 trial) for previously treated MSS metastatic CRC
• Findings from early-phase studies (eg, REGOMUNE, CAVE, ILLUMINATE-206) and ongoing evaluation of regimens combining immune checkpoint inhibitors with different systemic therapies (eg, regorafenib, cetuximab) for MSS metastatic CRC
• Key efficacy and safety findings from the Phase III BEACON CRC trial of encorafenib/cetuximab with or without binimetinib for metastatic CRC with the BRAF V600E mutation; FDA approval of encorafenib/cetuximab and appropriate integration into clinical practice
• Design, eligibility criteria and available efficacy results from the Phase II ANCHOR-CRC trial evaluating encorafenib, binimetinib and cetuximab for previously untreated metastatic CRC with the BRAF V600E mutation
• Incidence of HER2 overexpression and HER2 mutations in patients with CRC; key efficacy findings from the Phase II DESTINY-CRC01 study of T-DXd for HER2-expressing advanced CRC
• Spectrum, incidence and severity of toxicities associated with T-DXd in the DESTINY-CRC01 trial
• Available data with and ongoing investigation of HER2-directed approaches for advanced CRC (eg, the HERACLES, DASH, DESTINY-CRC02 and MOUNTAINEER trials)
• Long-term efficacy and safety findings with regorafenib and with TAS-102 and clinical, biologic and practical factors in sequencing these therapies
• Available data with and potential role of TAS-102 in combination with bevacizumab or other systemic agents in therapy for metastatic CRC and earlier disease stages
• Mechanism of action of napabucasin; implications of the negative results from the Phase III CanStem303C trial of napabucasin in combination with FOLFIRI with or without bevacizumab for previously treated metastatic CRC
• Other promising agents and strategies under investigation for CRC

Target Audience
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.

Learning Objectives

• Develop a long-term care plan for patients diagnosed with metastatic colorectal cancer (CRC), considering biomarker profile, tumor location, exposure to prior systemic therapy, symptomatology, performance status and personal goals of treatment.
• Recognize the recent FDA approval of nivolumab for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual disease after receiving neoadjuvant chemoradiotherapy.
• Acknowledge the recent FDA approval of pembrolizumab in combination with trastuzumab and fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma.
• Consider the recent FDA approval of pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or GEJ cancer who are not candidates for surgical resection or definitive chemoradiation therapy.
• Appreciate the recent FDA approval of nivolumab in combination with fluoropyrimidine- and platinum-containing chemotherapy for patients with previously untreated locally advanced or metastatic gastric cancer, GEJ cancer or esophageal adenocarcinoma.
• Recognize the recent FDA approval of trastuzumab deruxtecan for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma who have received a prior trastuzumab-based regimen.
• Recall the recent FDA approval of a new dosage schedule with cetuximab for patients with KRAS wild-type, EGFR-expressing metastatic CRC, and identify patients who are appropriate candidates for this regimen.
• Review the data supporting the FDA approval of pembrolizumab as first-line therapy for patients with unresectable or metastatic microsatellite instability (MSI)-high or mismatch repair-deficient CRC.
• Discuss published research data documenting the efficacy of combined BRAF/MEK/EGFR inhibition for patients with relapsed/refractory CRC and a BRAF V600E mutation to optimally incorporate this therapeutic strategy into clinical algorithms.
• Evaluate the utility of HER2 status, PD-L1 combined positive score, MSI status, clinical factors and patient preferences in the selection and sequencing of systemic therapy for locally advanced or metastatic gastric, GEJ, esophageal and colorectal cancer.
• Appraise available and emerging data with agents currently being investigated for gastrointestinal cancers, and refer eligible patients for clinical trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Dr Atreya — Advisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pionyr Immunotherapeutics; Research Funding (Institution): Bristol-Myers Squibb Company, Gossamer Bio, Guardant Health, Kura Oncology, Merck, Novartis. Dr Deming — Advisory Committee: Acrotech Biopharma, Bayer HealthCare Pharmaceuticals, MEI Pharma Inc, Pfizer Inc, Promega Corporation; Contracted Research: Arcus Biosciences, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Merck. Dr Van Cutsem — Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Pierre Fabre, Roche Laboratories Inc, Servier, Sirtex Medical Ltd, Taiho Oncology Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier. Dr Wainberg — Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Molecular Templates; Contracted Research: Arcus Biosciences, Five Prime Therapeutics Inc, Novartis, Plexxikon Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, Exelixis Inc, Lilly, Merck and Taiho Oncology Inc.